Swedish Orphan Biovitrum AB (publ)

OTCPK:BIOV.F Stock Report

Market Cap: US$9.7b

Swedish Orphan Biovitrum Management

Management criteria checks 4/4

Swedish Orphan Biovitrum's CEO is Guido Oelkers, appointed in May 2017, has a tenure of 7.58 years. total yearly compensation is SEK48.88M, comprised of 25.1% salary and 74.9% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $12.02M. The average tenure of the management team and the board of directors is 5.9 years and 4.1 years respectively.

Key information

Guido Oelkers

Chief executive officer

SEK 48.9m

Total compensation

CEO salary percentage25.1%
CEO tenure7.6yrs
CEO ownership0.1%
Management average tenure5.9yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Guido Oelkers's remuneration changed compared to Swedish Orphan Biovitrum's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

SEK 4b

Jun 30 2024n/an/a

SEK 2b

Mar 31 2024n/an/a

SEK 2b

Dec 31 2023SEK 49mSEK 12m

SEK 2b

Sep 30 2023n/an/a

SEK 3b

Jun 30 2023n/an/a

SEK 3b

Mar 31 2023n/an/a

SEK 3b

Dec 31 2022SEK 47mSEK 11m

SEK 3b

Sep 30 2022n/an/a

SEK 2b

Jun 30 2022n/an/a

SEK 3b

Mar 31 2022n/an/a

SEK 3b

Dec 31 2021SEK 42mSEK 10m

SEK 3b

Sep 30 2021n/an/a

SEK 3b

Jun 30 2021n/an/a

SEK 3b

Mar 31 2021n/an/a

SEK 3b

Dec 31 2020SEK 33mSEK 10m

SEK 3b

Sep 30 2020n/an/a

SEK 3b

Jun 30 2020n/an/a

SEK 3b

Mar 31 2020n/an/a

SEK 4b

Dec 31 2019SEK 33mSEK 10m

SEK 3b

Sep 30 2019n/an/a

SEK 3b

Jun 30 2019n/an/a

SEK 3b

Mar 31 2019n/an/a

SEK 3b

Dec 31 2018SEK 26mSEK 9m

SEK 2b

Sep 30 2018n/an/a

SEK 2b

Jun 30 2018n/an/a

SEK 2b

Mar 31 2018n/an/a

SEK 1b

Dec 31 2017SEK 16mSEK 5m

SEK 1b

Compensation vs Market: Guido's total compensation ($USD4.43M) is below average for companies of similar size in the US market ($USD12.85M).

Compensation vs Earnings: Guido's compensation has been consistent with company performance over the past year.

CEO

Guido Oelkers (59 yo)

7.6yrs

Tenure

SEK 48,883,000

Compensation

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Leadership Team

NamePositionTenureCompensationOwnership
Guido Oelkers
CEO & President7.6yrsSEK 48.88m0.12%
$ 12.0m
Henrik Stenqvist
Chief Financial Officer6.4yrsno data0.016%
$ 1.6m
Torbjörn Hallberg
General Counsel & Head of Legal Affairs5.9yrsno data0.0089%
$ 858.1k
Daniel Rankin
Head of Strategy & Corporate Development2.9yrsno data0.0029%
$ 276.4k
Lena Bjurner
Head of Human Resources1.9yrsno datano data
Armin Reininger
Senior Scientific & Medical Advisor7.9yrsno data0.0047%
$ 450.3k
Norbert Oppitz
Head of International7.2yrsno data0.012%
$ 1.1m
Sofiane Fahmy
Head of Europe5.9yrsno data0.0077%
$ 746.0k
Duane Barnes
Head of North America3.9yrsno datano data
Mahmood Ladha
Head of Strategic Transformation Operationsno datano data0.0018%
$ 175.9k
Christine Wesstrom
Head of Technical Operations2.8yrsno data0.0032%
$ 311.1k
Lydia Abad-Franch
Senior VP1.9yrsno datano data

5.9yrs

Average Tenure

56.5yo

Average Age

Experienced Management: BIOV.F's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hans Wigzell
Chairman of Scientific Advisory Board23.9yrsSEK 158.00kno data
Helena Saxon
Director13.7yrsSEK 828.00k0.0067%
$ 643.6k
Anders Ullman
Director1.6yrsSEK 463.00k0.0010%
$ 96.6k
Stephen O'Rahilly
Member of Scientific Advisory Boardno datano datano data
Ralf Pettersson
Member of Scientific Advisory Boardno datano datano data
Stefan Del Prato
Member of Scientific Advisory Boardno datano datano data
Jonathan Sanders Arch
Member of Scientific Advisory Boardno datano datano data
Annette Clancy
Independent Director10.6yrsSEK 770.00k0.00099%
$ 95.7k
Staffan Schuberg
Independent Director4.6yrsSEK 827.00k0.0021%
$ 201.0k
Filippa Stenberg
Director3.6yrsSEK 673.00k0.00017%
$ 16.4k
David Meek
Chairmanno datano datano data
Katy Mazibuko
Employee Representative Director1.9yrsno data0.0013%
$ 122.7k

4.1yrs

Average Tenure

58yo

Average Age

Experienced Board: BIOV.F's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 17:40
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander LindströmABG Sundal Collier
Rosie TurnerBarclays
Brian BalchinBarclays